ZONISAMIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zonisamide, and what generic alternatives are available?
Zonisamide is a drug marketed by Ani Pharms, Apotex Inc, Aurobindo Pharma Ltd, Bionpharma, Epic Pharma Llc, Glenmark Generics, Granules, Heritage Pharma Avet, Invagen Pharms, Mylan Pharms Inc, Rising, Roxane, Sun Pharm Inds (in), Sun Pharm Industries, Unichem, Upsher Smith Labs, and Zydus Lifesciences. and is included in eighteen NDAs.
The generic ingredient in ZONISAMIDE is zonisamide. There are nineteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the zonisamide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zonisamide
A generic version of ZONISAMIDE was approved as zonisamide by APOTEX INC on December 22nd, 2005.
Summary for ZONISAMIDE
Recent Clinical Trials for ZONISAMIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Washington State University | Phase 2 |
The University of Akron | Phase 2 |
Washington University School of Medicine | Phase 2 |
Pharmacology for ZONISAMIDE
Drug Class | Anti-epileptic Agent |
Mechanism of Action | Carbonic Anhydrase Inhibitors P-Glycoprotein Inhibitors |
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Anatomical Therapeutic Chemical (ATC) Classes for ZONISAMIDE
US Patents and Regulatory Information for ZONISAMIDE
EU/EMA Drug Approvals for ZONISAMIDE
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Amdipharm Limited | Zonegran | zonisamide | EMEA/H/C/000577 Zonegran is indicated as:monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged six years and above. |
Authorised | no | no | no | 2005-03-10 | |
Mylan Pharmaceuticals Limited | Zonisamide Mylan | zonisamide | EMEA/H/C/004127 Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above. |
Authorised | yes | no | no | 2016-03-31 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |